- Event

International Conference on Alzheimer’s Drug Discovery

Asceneuron to present at the 17th International Conference on Alzheimer’s Drug Discovery on 12-13 September, 2016 in Jersey City, NJ, USA

- Event

10th International Conference on Frontotemporal Dementias

Asceneuron to take part in a panel discussion on clinical trials at the 10th International Conference on Frontotemporal Dementias on August 31 - September 2, 2016, in Munich, Germany

- Event

1st European Conference on Drug Discovery for Neurodegeneration

Asceneuron to present at the 1st European Conference on Drug Discovery for Neurodegeneration on 15-17 May, 2016 in Budapest, Hungary

- Press releases

Asceneuron appoints Hans Schikan as Chairman to the Board of Directors

Asceneuron today announced the appointment of Hans Schikan (PharmD) as Non-Executive Chairman to the Board of Directors.

- News

"A l'EPFL, Asceneuron lève 30 millions" (Article in Le Matin Dimanche)

- Press releases

Asceneuron raises CHF 30 million

Asceneuron today announced the closing of a Series A financing of CHF 30 million (USD 30.6 million). The financing round was led by Sofinnova Partners which becomes the largest financial investor in the company. They are joined by new investors SR One, Kurma Partners and Johnson &
Johnson Innovation – JJDC, Inc. (JJDC). The company’s founding investors MS Ventures also participated.

- News

Asceneuron is awarded Alzheimer’s Drug Discovery Foundation Grant

Alzheimer’s Drug Discovery Foundation (ADDF) awarded a USD 325,000 grant to support the development of Asceneuron’s tau modulators.

- News

Asceneuron featured in BioCentury

Asceneuron is featured in a BioCentury emerging company profile by Emily Cukier-Meisner.

- Press releases

Asceneuron scoops One Nucleus BioNewsRound Award 2015

As announced at Genesis 2015, Asceneuron is this year’s winner of the coveted One Nucleus BioNewsRound Award.

- Press releases

Asceneuron appoints leading experts to Scientific Advisory Board

Asceneuron today announced the appointment of leading experts in the field of neurodegenerative diseases to its newly formed scientific advisory board (SAB): Prof. Christian Haass from Ludwig-Maximilians University (LMU) Munich; Prof. Adam Boxer from University of California, San Francisco (UCSF); and Prof. Günter U. Höglinger from the Technical University of Munich.